Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Eisai disclosed in its 1Q13 earnings for the period ending June 30 that it began a double-blind,
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury